Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Cancer Res

Retrieve available abstracts of 121 articles:
HTML format

Single Articles

    January 2023
  1. SUN Y, Li X, Yin C, Zhang J, et al
    AMPK phosphorylates ZDHHC13 to increase MC1R activity and suppress melanomagenesis.
    Cancer Res. 2023 Jan 26:CAN-22-2595. doi: 10.1158/0008-5472.CAN-22-2595.
    PubMed     Abstract available

  2. LLANO E, Todeschini AL, Felipe-Medina N, Corte-Torres MD, et al
    The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.
    Cancer Res. 2023;83:239-250.
    PubMed     Abstract available

    November 2022
  3. ABECUNAS C, Whitehead CE, Ziemke EK, Baumann DG, et al
    Loss of NF1 in melanoma confers sensitivity to SYK kinase inhibition.
    Cancer Res. 2022 Nov 21:CAN-22-0883. doi: 10.1158/0008-5472.CAN-22-0883.
    PubMed     Abstract available

  4. STEVENS LE, Peluffo G, Qiu X, Temko D, et al
    JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states.
    Cancer Res. 2022 Nov 21:CAN-22-0423. doi: 10.1158/0008-5472.CAN-22-0423.
    PubMed     Abstract available

  5. WANG F, Moon W, Letsou W, Sapkota Y, et al
    Genome-wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk.
    Cancer Res. 2022 Nov 10. pii: 710536. doi: 10.1158/0008-5472.CAN-22-1888.
    PubMed     Abstract available

  6. GONG P, Chin SL, Allen WM, Ballal H, et al
    Quantitative Micro-Elastography Enables In Vivo Detection of Residual Cancer in the Surgical Cavity during Breast-Conserving Surgery.
    Cancer Res. 2022;82:4093-4104.
    PubMed     Abstract available

  7. PERRONE M, Chiodoni C, Lecchi M, Botti L, et al
    ATF3 reprograms the bone marrow niche in response to early breast cancer transformation.
    Cancer Res. 2022 Nov 1. pii: 710151. doi: 10.1158/0008-5472.CAN-22-0651.
    PubMed     Abstract available

    October 2022
  8. HALPERIN C, Hey J, Weichenhan D, Stein Y, et al
    Global DNA Methylation Analysis of Cancer-Associated Fibroblasts Reveals Extensive Epigenetic Rewiring Linked with RUNX1 Upregulation in Breast Cancer Stroma.
    Cancer Res. 2022 Oct 26:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-0209.
    PubMed     Abstract available

  9. BASSIOUNI R, Idowu MO, Gibbs LD, Robila V, et al
    Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer.
    Cancer Res. 2022 Oct 25. pii: 710045. doi: 10.1158/0008-5472.CAN-22-2682.
    PubMed     Abstract available

  10. HARGROVE-WILEY E, Fingleton B
    Sex hormones in breast cancer immunity.
    Cancer Res. 2022 Oct 24. pii: 709945. doi: 10.1158/0008-5472.CAN-22-1829.
    PubMed     Abstract available

  11. TARANTINO P, Tolaney SM
    The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.
    Cancer Res. 2022;82:3659-3661.
    PubMed     Abstract available

  12. BLAWSKI R, Toska E
    A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
    Cancer Res. 2022;82:3668-3670.
    PubMed     Abstract available

  13. DURO-SANCHEZ S, Nadal-Serrano M, Lalinde-Gutierrez M, Arenas EJ, et al
    Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709715. doi: 10.1158/0008-5472.CAN-22-0787.
    PubMed     Abstract available

  14. HONG J, Lee JH, Zhang Z, Wu Y, et al
    PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709714. doi: 10.1158/0008-5472.CAN-22-0736.
    PubMed     Abstract available

  15. GAMBI G, Mengus G, Davidson G, Demesmaeker E, et al
    The lncRNA LENOX interacts with RAP2C to regulate metabolism and promote resistance to MAPK inhibition in melanoma.
    Cancer Res. 2022 Oct 10. pii: 709677. doi: 10.1158/0008-5472.CAN-22-0959.
    PubMed     Abstract available

  16. ELKHOLI IE, Lalonde A, Park M, Cote JF, et al
    Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s).
    Cancer Res. 2022 Oct 10. pii: 709673. doi: 10.1158/0008-5472.CAN-22-1902.
    PubMed     Abstract available

    September 2022
  17. TOKURA M, Nakayama J, Prieto-Vila M, Shiino S, et al
    Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.
    Cancer Res. 2022;82:3236-3248.
    PubMed     Abstract available

  18. SMALLEY I, Smalley KSM
    Space Is the Place: Mapping the Cell-Cell Interactions That Predict Immunotherapy Responses in Melanoma.
    Cancer Res. 2022;82:3198-3200.
    PubMed     Abstract available

  19. LIU H, Lyu H, Jiang G, Chen D, et al
    ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer.
    Cancer Res. 2022 Sep 7. pii: 709106. doi: 10.1158/0008-5472.CAN-22-0800.
    PubMed     Abstract available

  20. XU X, Wang K, Vera O, Verma A, et al
    Gain of Chromosome 1q Perturbs a Competitive Endogenous RNA Network to Promote Melanoma Metastasis.
    Cancer Res. 2022;82:3016-3031.
    PubMed     Abstract available

  21. SRIVASTAVA A, Tommasi C, Sessions D, Mah A, et al
    MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET.
    Cancer Res. 2022;82:3143-3157.
    PubMed     Abstract available

    August 2022
  22. XU X, Wang K, Vera O, Verma A, et al
    Gain of chromosome 1q perturbs a competitive endogenous RNA network to promote melanoma metastasis.
    Cancer Res. 2022 Aug 31. pii: 706990. doi: 10.1158/0008-5472.CAN-22-0283.
    PubMed     Abstract available

  23. GUO Q, Wang H, Duan J, Luo W, et al
    An alternatively spliced p62 isoform confers resistance to chemotherapy in breast cancer.
    Cancer Res. 2022 Aug 29. pii: 708925. doi: 10.1158/0008-5472.CAN-22-0909.
    PubMed     Abstract available

  24. NANDI A, Debnath R, Nayak A, To TKJ, et al
    Dll1-mediated Notch signaling drives tumor cell crosstalk with cancer associated fibroblasts to promote radioresistance in breast cancer.
    Cancer Res. 2022 Aug 24. pii: 708708. doi: 10.1158/0008-5472.CAN-21-1225.
    PubMed     Abstract available

  25. SCHATTON T, Itoh Y, Martins C, Rasbach E, et al
    Inhibition of melanoma cell-intrinsic Tim-3 stimulates MAPK-dependent tumorigenesis.
    Cancer Res. 2022 Aug 18. pii: 708039. doi: 10.1158/0008-5472.CAN-22-0970.
    PubMed     Abstract available

  26. ZENG E, He W, Sjolander A, Bergqvist J, et al
    Determinants and effectiveness of extending the duration of adjuvant hormone therapy beyond 5 years in breast cancer patients.
    Cancer Res. 2022 Aug 18. pii: 708038. doi: 10.1158/0008-5472.CAN-22-0900.
    PubMed     Abstract available

    Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
    Cancer Res. 2022;82:2811-2820.
    PubMed     Abstract available

  28. ALTWEGG KA, Viswanadhapalli S, Mann M, Chakravarty D, et al
    A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer.
    Cancer Res. 2022 Aug 11. pii: 707658. doi: 10.1158/0008-5472.CAN-22-0698.
    PubMed     Abstract available

  29. NARDONE A, Qiu X, Spisak S, Nagy Z, et al
    A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Cancer Res. 2022 Aug 11. pii: 707656. doi: 10.1158/0008-5472.CAN-21-3186.
    PubMed     Abstract available

  30. WU C, Jarrett AM, Zhou Z, Elshafeey N, et al
    MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer.
    Cancer Res. 2022 Aug 1. pii: 707362. doi: 10.1158/0008-5472.CAN-22-1329.
    PubMed     Abstract available

    July 2022
  31. TIMPERI E, Gueguen P, Molgora M, Magagna I, et al
    Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer.
    Cancer Res. 2022 Jul 21. pii: 707127. doi: 10.1158/0008-5472.CAN-22-1427.
    PubMed     Abstract available

  32. ANTORANZ A, Van Herck Y, Bolognesi MM, Lynch SM, et al
    Mapping the immune landscape in metastatic melanoma reveals localized cell-cell interactions that predict immunotherapy response.
    Cancer Res. 2022 Jul 14. pii: 707010. doi: 10.1158/0008-5472.CAN-22-0363.
    PubMed     Abstract available

  33. CHEN F, Park SL, Wilkens LR, Wan P, et al
    Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
    Cancer Res. 2022 Jul 14. pii: 707009. doi: 10.1158/0008-5472.CAN-21-4461.
    PubMed     Abstract available

    June 2022
  34. KALRA R, Chen CH, Wang J, Salam AB, et al
    Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer.
    Cancer Res. 2022 Jun 23. pii: 705013. doi: 10.1158/0008-5472.CAN-21-3106.
    PubMed     Abstract available

  35. CLARIDGE SE, Hopkins BD
    PI3King the Environment for Growth: PI3K Activation Drives Transcriptome Changes That Support Oncogenic Growth.
    Cancer Res. 2022;82:2216-2218.
    PubMed     Abstract available

  36. LADEWIG E, Michelini F, Jhaveri K, Castel P, et al
    The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
    Cancer Res. 2022;82:2269-2280.
    PubMed     Abstract available

  37. ZHANG Z, Golomb L, Meyerson M
    Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
    Cancer Res. 2022;82:2171-2184.
    PubMed     Abstract available

  38. CAI W, Nguyen MQ, Wilski NA, Purwin TJ, et al
    A Genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1/2 inhibitors in NRAS mutant melanoma.
    Cancer Res. 2022 Jun 3. pii: 699338. doi: 10.1158/0008-5472.CAN-21-3217.
    PubMed     Abstract available

    May 2022
  39. BONFILL-TEIXIDOR E, Iurlaro R, Handl C, Wichmann J, et al
    Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis.
    Cancer Res. 2022 May 18. pii: 699020. doi: 10.1158/0008-5472.CAN-21-4152.
    PubMed     Abstract available

  40. KOPANJA D, Chand V, O'Brien EM, Mukhopadhyay NK, et al
    Transcriptional repression by FoxM1 suppresses tumor differentiation and promotes metastasis of breast cancer.
    Cancer Res. 2022 May 18. pii: 699021. doi: 10.1158/0008-5472.CAN-22-0410.
    PubMed     Abstract available

  41. WEI YT, Wang XR, Yan C, Huang F, et al
    Thymosin alpha-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis.
    Cancer Res. 2022;82:1991-2002.
    PubMed     Abstract available

  42. FATHERREE JP, Guarin JR, McGinn RA, Naber SP, et al
    Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase.
    Cancer Res. 2022;82:2031-2044.
    PubMed     Abstract available

  43. ROVERA C, Berestjuk I, Lecacheur M, Tavernier C, et al
    Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3-Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells.
    Cancer Res. 2022;82:1774-1788.
    PubMed     Abstract available

  44. MARCZYK M, Gunasekharan V, Casadevall D, Qing T, et al
    Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.
    Cancer Res. 2022;82:1698-1711.
    PubMed     Abstract available

  45. ISKANDER K, Paquet M, Brayton C, Jaiswal AK, et al
    Editor's Note: Deficiency of NRH: Quinone Oxidoreductase 2 Increases Susceptibility to 7,12-Dimethylbenz(a)anthracene and Benzo(a)pyrene-Induced Skin Carcinogenesis.
    Cancer Res. 2022;82:1845.

  46. LUND AW
    Be Easy and Chill: Melanoma Cells Tell Lymph Node Fibroblasts to Relax.
    Cancer Res. 2022;82:1692-1694.
    PubMed     Abstract available

    April 2022
  47. RODRIGUEZ-TIRADO C, Kale N, Carlini MJ, Shrivastava N, et al
    NR2F1 is a barrier to dissemination of early stage breast cancer cells.
    Cancer Res. 2022 Apr 26. pii: 694636. doi: 10.1158/0008-5472.CAN-21-4145.
    PubMed     Abstract available

  48. SINGH S, Lee N, Pedroza DA, Bado IL, et al
    Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer.
    Cancer Res. 2022 Apr 20. pii: 694629. doi: 10.1158/0008-5472.CAN-21-3714.
    PubMed     Abstract available

  49. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    PubMed     Abstract available

  50. QUIROS-GONZALEZ I, Tomaszewski MR, Golinska MA, Brown E, et al
    Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.
    Cancer Res. 2022;82:1658-1668.
    PubMed     Abstract available

  51. WANG H, Xu H, Chen W, Cheng M, et al
    Rab13 sustains breast cancer stem cells by supporting tumor-stroma crosstalk.
    Cancer Res. 2022 Apr 8. pii: 694330. doi: 10.1158/0008-5472.CAN-21-4097.
    PubMed     Abstract available

  52. ELWAKEEL E, Bruggemann M, Wagih J, Lityagina O, et al
    Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis.
    Cancer Res. 2022;82:1380-1395.
    PubMed     Abstract available

  53. HONG Z, Liu T, Wan L, Fa P, et al
    Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy.
    Cancer Res. 2022;82:1298-1312.
    PubMed     Abstract available

    March 2022
  54. WILSON Z, Odedra R, Wallez Y, Wijnhoven PWG, et al
    ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Cancer Res. 2022;82:1140-1152.
    PubMed     Abstract available

    February 2022
  55. BHATIA S, Kramer M, Russo S, Naik P, et al
    Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor-intrinsic characteristics.
    Cancer Res. 2022 Feb 18. pii: 681619. doi: 10.1158/0008-5472.CAN-21-2807.
    PubMed     Abstract available

  56. SCHEIDMANN MC, Castro-Giner F, Strittmatter K, Krol I, et al
    An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression.
    Cancer Res. 2022;82:681-694.
    PubMed     Abstract available

  57. LIAO C, Glodowski CR, Fan C, Liu J, et al
    Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
    Cancer Res. 2022;82:665-680.
    PubMed     Abstract available

  58. BOONEN RACM, Wiegant WW, Celosse N, Vroling B, et al
    Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Cancer Res. 2022;82:615-631.
    PubMed     Abstract available

  59. GILL JG, Leef SN, Ramesh V, Martin-Sandoval MS, et al
    A short isoform of spermatogenic enzyme GAPDHS functions as a metabolic switch and limits metastasis in melanoma.
    Cancer Res. 2022 Feb 11. pii: 0008-5472.CAN-21-2062.
    PubMed     Abstract available

  60. LI XQ, Zhang R, Lu H, Yue XM, et al
    Extracellular vesicle-packaged CDH11 and ITGA5 induce the premetastatic niche for bone colonization of breast cancer cells.
    Cancer Res. 2022 Feb 11. pii: 0008-5472.CAN-21-1331.
    PubMed     Abstract available

    January 2022
  61. LI Z, Wu Y, Yates ME, Tasdemir N, et al
    Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.
    Cancer Res. 2022 Jan 25. pii: 0008-5472.CAN-21-2576.
    PubMed     Abstract available

  62. LIU T, Zhou L, Xiao Y, Andl T, et al
    BRAF Inhibitors Reprogram Cancer-Associated Fibroblasts to Drive Matrix Remodeling and Therapeutic Escape in Melanoma.
    Cancer Res. 2022 Jan 21. pii: 0008-5472.CAN-21-0614.
    PubMed     Abstract available

  63. MAJORINI MT, Colombo MP, Lecis D
    Few, but efficient: the role of mast cells in breast cancer and other solid tumors.
    Cancer Res. 2022 Jan 19. pii: 0008-5472.CAN-21-3424.
    PubMed     Abstract available

  64. HAJ-SHOMALY J, Vorontsova A, Barenholz-Cohen T, Levi-Galibov O, et al
    T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy.
    Cancer Res. 2022;82:278-291.
    PubMed     Abstract available

  65. ZHU WJ, Chen X, Guo XY, Liu HT, et al
    Low glucose-induced overexpression of HOXC-AS3 promotes metabolic reprogramming of breast cancer.
    Cancer Res. 2022 Jan 14. pii: 0008-5472.CAN-21-1179.
    PubMed     Abstract available

    December 2021
  66. XU Y, Ren W, Li Q, Duan C, et al
    LncRNA Uc003xsl.1-mediated activation of the NF-kappaB/IL8 axis promotes progression of triple-negative breast cancer.
    Cancer Res. 2021 Dec 29. pii: 0008-5472.CAN-21-1446.
    PubMed     Abstract available

  67. BEETHAM H, Griffith BGC, Murina O, Loftus AE, et al
    Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-0373.
    PubMed     Abstract available

  68. OBA T, Kajihara R, Yokoi T, Repasky EA, et al
    Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors.
    Cancer Res. 2021;81:6183-6195.
    PubMed     Abstract available

  69. MOORE J, Ma L, Lazar A, Barcellos-Hoff MH, et al
    Mammary tumor-derived transplants as breast cancer models to evaluate tumor-immune interactions and therapeutic responses.
    Cancer Res. 2021 Dec 13. pii: 0008-5472.CAN-21-0253.
    PubMed     Abstract available

    November 2021
  70. CHOI SR, Hwang CY, Lee J, Cho KH, et al
    Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability.
    Cancer Res. 2021 Nov 29. pii: 0008-5472.CAN-21-0621.
    PubMed     Abstract available

  71. LIU W, Stachura P, Xu HC, Varaljai R, et al
    BAFF attenuates immunosuppressive monocytes in the melanoma tumor microenvironment.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-1171.
    PubMed     Abstract available

  72. YUAN H, Yan L, Wu M, Shang Y, et al
    Analysis of the estrogen receptor-associated lncRNA landscape identifies a role for ERLC1 in breast cancer progression.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-1155.
    PubMed     Abstract available

  73. TUBITA A, Lombardi Z, Tusa I, Lazzeretti A, et al
    Inhibition of ERK5 elicits cellular senescence in melanoma via the cyclin-dependent kinase inhibitor p21.
    Cancer Res. 2021 Nov 19. pii: 0008-5472.CAN-21-0993.
    PubMed     Abstract available

  74. SUBRAMANIAN S, Daquinag AC, AghaAmiri S, Ghosh SC, et al
    Characterization of Peptides Targeting Metastatic Tumor Cells as Probes for Cancer Detection and Vehicles for Therapy Delivery.
    Cancer Res. 2021;81:5756-5764.
    PubMed     Abstract available

  75. JANJANAM J, Pano G, Wang R, Minden-Birkenmaier BA, et al
    Matricellular Protein WISP2 Is an Endogenous Inhibitor of Collagen Linearization and Cancer Metastasis.
    Cancer Res. 2021;81:5666-5677.
    PubMed     Abstract available

  76. YOKOYAMA S, Takahashi A, Kikuchi R, Nishibu S, et al
    SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 axis.
    Cancer Res. 2021 Nov 2. pii: 0008-5472.CAN-21-2078.
    PubMed     Abstract available

  77. DAMODARAN S, Hortobagyi GN
    Estrogen Receptor: A Paradigm for Targeted Therapy.
    Cancer Res. 2021;81:5396-5398.
    PubMed     Abstract available

  78. GRISARU-TAL S, Dulberg S, Beck L, Zhang C, et al
    Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity.
    Cancer Res. 2021;81:5555-5571.
    PubMed     Abstract available

  79. TEMPS C, Lietha D, Webb ER, Li XF, et al
    A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
    Cancer Res. 2021;81:5438-5450.
    PubMed     Abstract available

  80. HINSHAW DC, Hanna A, Lama-Sherpa T, Metge B, et al
    Hedgehog Signaling Regulates Metabolism and Polarization of Mammary Tumor-Associated Macrophages.
    Cancer Res. 2021;81:5425-5437.
    PubMed     Abstract available

    October 2021
  81. DONE SJ, Kanwar N, Balde Z, Nair R, et al
    Heterogeneity of circulating tumor cell-associated genomic gains in breast cancer and its association with the host immune response.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1079.
    PubMed     Abstract available

  82. GOU X, Anurag M, Lei JT, Kim BJ, et al
    Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1256.
    PubMed     Abstract available

  83. PATEL A, Garcia-Closas M, Olshan AF, Perou CM, et al
    Gene level germline contributions to clinical risk of recurrence scores in Black and White breast cancer patients.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1207.
    PubMed     Abstract available

  84. AGUIRRE-PORTOLES C, Payne R, Trautz A, Foskett JK, et al
    ZIP9 is a Druggable Determinant of Sex Differences in Melanoma.
    Cancer Res. 2021 Oct 27. pii: 0008-5472.CAN-21-0982.
    PubMed     Abstract available

  85. HUGGINS DN, LaRue RS, Wang Y, Knutson TP, et al
    Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset.
    Cancer Res. 2021;81:5284-5295.
    PubMed     Abstract available

  86. SALTARI A, Dzung A, Quadri M, Tiso N, et al
    Specific activation of the CD271 intracellular domain in combination with chemotherapy or targeted therapy inhibits melanoma progression.
    Cancer Res. 2021 Oct 13. pii: 0008-5472.CAN-21-0117.
    PubMed     Abstract available

  87. VALENCIA JC, Erwin-Cohen RA, Clavijo PE, Allen C, et al
    Myeloid derived suppressive cell expansion promotes melanoma growth and severity of autoimmunity by inhibiting CD40/IL-27 regulation in macrophages.
    Cancer Res. 2021 Oct 12. pii: 0008-5472.CAN-21-1148.
    PubMed     Abstract available

  88. WOITEK R, McLean MA, Ursprung S, Rueda OM, et al
    Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients.
    Cancer Res. 2021 Oct 8. pii: 0008-5472.CAN-21-1499.
    PubMed     Abstract available

    September 2021
  89. LIU C, Qiang J, Deng Q, Xia J, et al
    ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression.
    Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-1337.
    PubMed     Abstract available

  90. ZHAO X, Li J, Liu Z, Powers S, et al
    Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-2555.
    PubMed     Abstract available

  91. ANSARI KI, Bhan A, Saotome M, Tyagi A, et al
    Autocrine GMCSF Signaling Contributes to Growth of HER2(+) Breast Leptomeningeal Carcinomatosis.
    Cancer Res. 2021;81:4723-4735.
    PubMed     Abstract available

  92. EVANS KW, Yuca E, Scott SS, Zhao M, et al
    Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple negative breast cancer.
    Cancer Res. 2021 Sep 13. pii: 0008-5472.CAN-20-3242.
    PubMed     Abstract available

  93. FAURE C, Djerbi-Bouillie R, Domingot A, Bouzinba-Segard H, et al
    Allosteric inhibition of HER2 by Moesin-mimicking compounds targets HER2-positive cancers and brain metastases.
    Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0162.
    PubMed     Abstract available

    August 2021
  94. ZUO H, Yang D, Wan Y
    Fam20C regulates bone resorption and breast cancer bone metastasis through osteopontin and BMP4.
    Cancer Res. 2021 Aug 25. pii: 0008-5472.CAN-20-3328.
    PubMed     Abstract available

  95. YU TJ, Liu YY, Li XG, Lian B, et al
    PDSS1-mediated activation of CAMK2A-STAT3 signaling promotes metastasis in triple-negative breast cancer.
    Cancer Res. 2021 Aug 18. pii: 0008-5472.CAN-21-0747.
    PubMed     Abstract available

  96. AHIRWAR DK, Charan M, Mishra S, Verma AK, et al
    Slit2 inhibits breast cancer metastasis by activating M1-like phagocytic and anti-fibrotic macrophages.
    Cancer Res. 2021 Aug 16. pii: 0008-5472.CAN-20-3909.
    PubMed     Abstract available

  97. PULEO J, Polyak K
    The MCF10 Model of Breast Tumor Progression.
    Cancer Res. 2021;81:4183-4185.
    PubMed     Abstract available

  98. APOSTOLIDI M, Vathiotis IA, Muthusamy V, Gaule P, et al
    Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
    Cancer Res. 2021;81:4346-4359.
    PubMed     Abstract available

  99. TANG K, Zhu L, Chen J, Wang D, et al
    Hypoxia promotes breast cancer cell growth by activating a glycogen metabolic program.
    Cancer Res. 2021 Aug 4. pii: 0008-5472.CAN-21-0753.
    PubMed     Abstract available

  100. WANG Y, Kartasalo K, Weitz P, Acs B, et al
    Predicting molecular phenotypes from histopathology images: a transcriptome-wide expression-morphology analysis in breast cancer.
    Cancer Res. 2021 Aug 2. pii: 0008-5472.CAN-21-0482.
    PubMed     Abstract available

    July 2021
  101. GOMEZ TEJEDA ZANUDO J, Mao P, Alcon C, Kowalski K, et al
    Cell line-specific network models of ER+ breast cancer identify potential PI3Kalpha inhibitor resistance mechanisms and drug combinations.
    Cancer Res. 2021 Jul 13. pii: 0008-5472.CAN-21-1208.
    PubMed     Abstract available

  102. TAKAYAMA KI, Honma T, Suzuki T, Kondoh Y, et al
    Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth.
    Cancer Res. 2021;81:3495-3508.
    PubMed     Abstract available

  103. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
    Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
    Cancer Res. 2021;81:3449-3460.
    PubMed     Abstract available

  104. CHOI H, Kwon J, Cho MS, Sun Y, et al
    Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.
    Cancer Res. 2021;81:3607-3620.
    PubMed     Abstract available

  105. YOO KH, Tang JJ, Rashid MA, Cho CH, et al
    Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments.
    Cancer Res. 2021;81:3727-3737.
    PubMed     Abstract available

    June 2021
  106. LAINE A, Nagelli SG, Farrington C, Butt U, et al
    CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis.
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-3651.
    PubMed     Abstract available

  107. CANO A, Lopez-Menendez C, Vazquez-Naharro A, Santos V, et al
    E2A modulates stemness, metastasis, and therapeutic resistance of breast cancer.
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-2685.
    PubMed     Abstract available

  108. SHARIF GM, Campbell MJ, Nasir A, Sengupta S, et al
    An AIB1 isoform alters enhancer access and enables progression of early stage triple-negative breast cancer.
    Cancer Res. 2021 Jun 16. pii: 0008-5472.CAN-20-3625.
    PubMed     Abstract available

  109. BHAN A, Ansari KI, Chen MY, Jandial R, et al
    Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2(+) Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression.
    Cancer Res. 2021;81:3200-3214.
    PubMed     Abstract available

  110. ZHOU Q, Howard ME, Tu X, Zhu Q, et al
    Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.
    Cancer Res. 2021;81:3333-3346.
    PubMed     Abstract available

  111. HARRIS RJ, Cheung A, Ng JCF, Laddach R, et al
    Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes In Triple-Negative Breast Cancer.
    Cancer Res. 2021 Jun 15. pii: 0008-5472.CAN-20-3773.
    PubMed     Abstract available

  112. WANG T, Farvid MS, Kang JH, Holmes MD, et al
    Diabetes Risk Reduction Diet and Survival After Breast Cancer Diagnosis.
    Cancer Res. 2021 Jun 9. pii: 0008-5472.CAN-21-0256.
    PubMed     Abstract available

    May 2021
  113. YANG B, Li X, Fu Y, Guo E, et al
    MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
    Cancer Res. 2021;81:2714-2729.
    PubMed     Abstract available

  114. SHAN P, Yang F, Qi H, Hu Y, et al
    Alteration of MDM2 by the small molecule YF438 exerts anti-tumor effects in triple-negative breast cancer.
    Cancer Res. 2021 May 13. pii: 0008-5472.CAN-20-0922.
    PubMed     Abstract available

  115. HAPACH LA, Carey SP, Schwager SC, Taufalele PV, et al
    Phenotypic heterogeneity and metastasis of breast cancer cells.
    Cancer Res. 2021 May 11. pii: 0008-5472.CAN-20-1799.
    PubMed     Abstract available

  116. GUO Q, Bartish M, Goncalves C, Huang F, et al
    The MNK1/2-eIF4E axis supports immune suppression and metastasis in postpartum breast cancer.
    Cancer Res. 2021 May 11. pii: 0008-5472.CAN-20-3143.
    PubMed     Abstract available

    April 2021
  117. CHEN F, Chen Z, Guan T, Zhou Y, et al
    N6-methyladenosine regulates mRNA stability and translation efficiency of KRT7 to promote breast cancer lung metastasis.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-3779.
    PubMed     Abstract available

    March 2021
  118. LI CI, Flanagan MR, Tang MC, Porter PL, et al
    Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma In Situ.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-20-4100.
    PubMed     Abstract available

  119. HU L, Su L, Cheng H, Mo C, et al
    Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers.
    Cancer Res. 2021 Mar 16. pii: 0008-5472.CAN-20-2123.
    PubMed     Abstract available

    February 2021
  120. YU R, Longo J, van Leeuwen JE, Zhang C, et al
    Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching.
    Cancer Res. 2021 Feb 18. pii: 0008-5472.CAN-20-2642.
    PubMed     Abstract available

    January 2021
  121. XING F, Zhao D, Wu SY, Tyagi A, et al
    Epigenetic and post-transcriptional modulation of SOS1 can promote breast cancer metastasis through obesity-activated c-Met signaling in African American women.
    Cancer Res. 2021 Jan 14. pii: 0008-5472.CAN-19-4031.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.